| P2093 | author name string | E Michael Lewiecki | |
| P2860 | cites work | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 |
| | Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin | Q28295204 |
| | Denosumab in postmenopausal women with low bone mineral density | Q28298728 |
| | The long and the short of bone therapy | Q28298737 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Osteoclast differentiation and activation | Q29547556 |
| | Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling | Q34384039 |
| | Perspective. How many women have osteoporosis? | Q35437028 |
| | Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. | Q35848843 |
| | The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management | Q36069258 |
| | Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength | Q36269835 |
| | The role of the immune system in the pathophysiology of osteoporosis | Q36324969 |
| | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 |
| | Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. | Q40296427 |
| | Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 |
| | How many women have osteoporosis now? | Q40528035 |
| | Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation | Q40556337 |
| | Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy | Q41087577 |
| | The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 |
| | Compliance with drug therapies for the treatment and prevention of osteoporosis | Q44256311 |
| | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 |
| | Compliance with pharmacologic therapy for osteoporosis | Q44593075 |
| | OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats | Q46099755 |
| | A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 |
| | Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass | Q46641001 |
| | A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer | Q46952812 |
| | The impact of compliance with osteoporosis therapy on fracture rates in actual practice | Q49211514 |
| | Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. | Q54137269 |
| P433 | issue | 4 | |
| P921 | main subject | osteoporosis | Q165328 |
| P304 | page(s) | 517-525 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Women's Health | Q15762155 |
| P1476 | title | Denosumab: a promising drug for the prevention and treatment of osteoporosis | |
| P478 | volume | 2 | |